AustralieFrV1, PubMed, Curation, bibRecord, 003426

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.

Identifieur interne : 003426 ( PubMed/Curation ); précédent : 003425; suivant : 003427

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.

Auteurs : John F. Seymour [Australie] ; Michael Pfreundschuh [Allemagne] ; Marek Trn N [République tchèque] ; Laurie H. Sehn [Canada] ; John Catalano [Australie] ; Eva Csinady [Suisse] ; Nicola Moore [Suisse] ; Bertrand Coiffier [France]

Source :

Haematologica [ 1592-8721 ] ; 2014.

RBID : pubmed:24895339

Descripteurs français

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors (administration & dosage), Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Murine-Derived (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Bevacizumab, Cyclophosphamide (administration & dosage), Doxorubicin (administration & dosage), Female, Humans, Lymphoma, Large B-Cell, Diffuse (diagnosis), Lymphoma, Large B-Cell, Diffuse (drug therapy), Male, Middle Aged, Prednisone (administration & dosage), Treatment Outcome, Vincristine (administration & dosage), Young Adult.
MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Cyclophosphamide, Doxorubicin, Prednisone, Vincristine.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- diagnosis : Lymphoma, Large B-Cell, Diffuse.
- drug therapy : Lymphoma, Large B-Cell, Diffuse.
- Adolescent, Adult, Aged, Aged, 80 and over, Bevacizumab, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.

Abstract

Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.

DOI: 10.3324/haematol.2013.100818
PubMed: 24895339

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003539

Links to Exploration step

pubmed:24895339

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.</title>
<author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name>
<affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.</nlm:affiliation>
<orgName type="university">Université de Melbourne</orgName>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pfreundschuh, Michael" sort="Pfreundschuh, Michael" uniqKey="Pfreundschuh M" first="Michael" last="Pfreundschuh">Michael Pfreundschuh</name>
<affiliation wicri:level="1"><nlm:affiliation>Saarland University Hospital, Homburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Saarland University Hospital, Homburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trn N, Marek" sort="Trn N, Marek" uniqKey="Trn N M" first="Marek" last="Trn N">Marek Trn N</name>
<affiliation wicri:level="1"><nlm:affiliation>General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>General Hospital, Charles University First Faculty of Medicine, Prague</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sehn, Laurie H" sort="Sehn, Laurie H" uniqKey="Sehn L" first="Laurie H" last="Sehn">Laurie H. Sehn</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre for Lymphoid Cancer, British Columbia Cancer Agency</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name>
<affiliation wicri:level="1"><nlm:affiliation>Frankston Hospital and Monash University, Frankston, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Frankston Hospital and Monash University, Frankston</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Csinady, Eva" sort="Csinady, Eva" uniqKey="Csinady E" first="Eva" last="Csinady">Eva Csinady</name>
<affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
<affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Lyon-Sud, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier Lyon-Sud, Lyon</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24895339</idno>
<idno type="pmid">24895339</idno>
<idno type="doi">10.3324/haematol.2013.100818</idno>
<idno type="wicri:Area/PubMed/Corpus">003539</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003539</idno>
<idno type="wicri:Area/PubMed/Curation">003426</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003426</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.</title>
<author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name>
<affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.</nlm:affiliation>
<orgName type="university">Université de Melbourne</orgName>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pfreundschuh, Michael" sort="Pfreundschuh, Michael" uniqKey="Pfreundschuh M" first="Michael" last="Pfreundschuh">Michael Pfreundschuh</name>
<affiliation wicri:level="1"><nlm:affiliation>Saarland University Hospital, Homburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Saarland University Hospital, Homburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trn N, Marek" sort="Trn N, Marek" uniqKey="Trn N M" first="Marek" last="Trn N">Marek Trn N</name>
<affiliation wicri:level="1"><nlm:affiliation>General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>General Hospital, Charles University First Faculty of Medicine, Prague</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sehn, Laurie H" sort="Sehn, Laurie H" uniqKey="Sehn L" first="Laurie H" last="Sehn">Laurie H. Sehn</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre for Lymphoid Cancer, British Columbia Cancer Agency</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name>
<affiliation wicri:level="1"><nlm:affiliation>Frankston Hospital and Monash University, Frankston, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Frankston Hospital and Monash University, Frankston</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Csinady, Eva" sort="Csinady, Eva" uniqKey="Csinady E" first="Eva" last="Csinady">Eva Csinady</name>
<affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
<affiliation wicri:level="1"><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier Lyon-Sud, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Hospitalier Lyon-Sud, Lyon</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Haematologica</title>
<idno type="eISSN">1592-8721</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Angiogenesis Inhibitors (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antibodies, Monoclonal, Murine-Derived (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Bevacizumab</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Doxorubicin (administration & dosage)</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphoma, Large B-Cell, Diffuse (diagnosis)</term>
<term>Lymphoma, Large B-Cell, Diffuse (drug therapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prednisone (administration & dosage)</term>
<term>Treatment Outcome</term>
<term>Vincristine (administration & dosage)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Anticorps monoclonaux d'origine murine (administration et posologie)</term>
<term>Anticorps monoclonaux humanisés (administration et posologie)</term>
<term>Bévacizumab</term>
<term>Cyclophosphamide (administration et posologie)</term>
<term>Doxorubicine (administration et posologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Inhibiteurs de l'angiogenèse (administration et posologie)</term>
<term>Jeune adulte</term>
<term>Lymphome B diffus à grandes cellules (diagnostic)</term>
<term>Lymphome B diffus à grandes cellules (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Prednisone (administration et posologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Vincristine (administration et posologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Cyclophosphamide</term>
<term>Doxorubicin</term>
<term>Prednisone</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux d'origine murine</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Cyclophosphamide</term>
<term>Doxorubicine</term>
<term>Inhibiteurs de l'angiogenèse</term>
<term>Prednisone</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphome B diffus à grandes cellules</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphome B diffus à grandes cellules</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Bevacizumab</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Bévacizumab</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24895339</PMID>
<DateCreated><Year>2014</Year>
<Month>08</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>04</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>99</Volume>
<Issue>8</Issue>
<PubDate><Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Haematologica</Title>
<ISOAbbreviation>Haematologica</ISOAbbreviation>
</Journal>
<ArticleTitle>R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.</ArticleTitle>
<Pagination><MedlinePgn>1343-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2013.100818</ELocationID>
<Abstract><AbstractText>Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.</AbstractText>
<CopyrightInformation>Copyright© Ferrata Storti Foundation.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seymour</LastName>
<ForeName>John F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pfreundschuh</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Saarland University Hospital, Homburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Trnĕný</LastName>
<ForeName>Marek</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sehn</LastName>
<ForeName>Laurie H</ForeName>
<Initials>LH</Initials>
<AffiliationInfo><Affiliation>Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catalano</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Frankston Hospital and Monash University, Frankston, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Csinady</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moore</LastName>
<ForeName>Nicola</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coiffier</LastName>
<ForeName>Bertrand</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Lyon-Sud, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>MAIN Study Investigators</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00486759</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Italy</Country>
<MedlineTA>Haematologica</MedlineTA>
<NlmUniqueID>0417435</NlmUniqueID>
<ISSNLinking>0390-6078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C571759">R-CHOP protocol</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8N3DW7272P</RegistryNumber>
<NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VB0R961HZT</RegistryNumber>
<NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 2008 Jan;88(1):38-47</RefSource>
<PMID Version="1">17998899</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Apr 20;25(12):1539-44</RefSource>
<PMID Version="1">17442997</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2008 Feb;9(2):105-16</RefSource>
<PMID Version="1">18226581</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Nov 27;359(22):2313-23</RefSource>
<PMID Version="1">19038878</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Mar 10;27(8):1227-34</RefSource>
<PMID Version="1">19188680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2009 Mar;50(3):366-73</RefSource>
<PMID Version="1">19347725</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2009 May;50(5):728-35</RefSource>
<PMID Version="1">19373598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Immunol Ther Exp (Warsz). 2009 Nov-Dec;57(6):435-45</RefSource>
<PMID Version="1">19866340</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2010 Mar;46(5):974-82</RefSource>
<PMID Version="1">20064707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Feb 20;29(6):632-8</RefSource>
<PMID Version="1">21205755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2011 Jul;96(7):996-1001</RefSource>
<PMID Version="1">21546504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hypertens Res. 2012 Feb;35(2):194-200</RefSource>
<PMID Version="1">22089532</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Mol Cell Cardiol. 2012 May;52(5):1164-75</RefSource>
<PMID Version="1">22326847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Aug 9;120(6):1210-7</RefSource>
<PMID Version="1">22734071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Dec;13(12):1250-9</RefSource>
<PMID Version="1">23168367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2000 Mar 2;342(9):626-33</RefSource>
<PMID Version="1">10699162</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Jan 24;346(4):235-42</RefSource>
<PMID Version="1">11807147</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 2002 Sep-Oct;22(5):2899-901</RefSource>
<PMID Version="1">12530014</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2003 Feb;14(2):277-81</RefSource>
<PMID Version="1">12562656</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2420-9</RefSource>
<PMID Version="1">12881220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Jun 3;350(23):2335-42</RefSource>
<PMID Version="1">15175435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Nov 1;104(9):2893-902</RefSource>
<PMID Version="1">15238424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 1973 Aug;32(2):302-14</RefSource>
<PMID Version="1">4353012</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1979 Nov;91(5):710-7</RefSource>
<PMID Version="1">496103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1993 Sep 30;329(14):987-94</RefSource>
<PMID Version="1">8141877</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pathol. 1997 Sep;183(1):44-50</RefSource>
<PMID Version="1">9370946</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jun 20;23(18):4117-26</RefSource>
<PMID Version="1">15867204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 1;23(22):5027-33</RefSource>
<PMID Version="1">15955905</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2006 May;7(5):379-91</RefSource>
<PMID Version="1">16648042</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 Jul 1;24(19):3121-7</RefSource>
<PMID Version="1">16754935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2006 Jun;47(6):998-1005</RefSource>
<PMID Version="1">16840188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2006 Oct;20(10):1759-66</RefSource>
<PMID Version="1">16932349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2006 Dec 14;355(24):2542-50</RefSource>
<PMID Version="1">17167137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H333-41</RefSource>
<PMID Version="1">16951052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Feb 10;25(5):579-86</RefSource>
<PMID Version="1">17242396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2007 Apr;170(4):1362-9</RefSource>
<PMID Version="1">17392174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2008 Mar;134(3):381-7</RefSource>
<PMID Version="1">17694324</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016403" MajorTopicYN="N">Lymphoma, Large B-Cell, Diffuse</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4116833</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24895339</ArticleId>
<ArticleId IdType="pii">haematol.2013.100818</ArticleId>
<ArticleId IdType="doi">10.3324/haematol.2013.100818</ArticleId>
<ArticleId IdType="pmc">PMC4116833</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003426 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003426 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:24895339
   |texte=   R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:24895339" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki